Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Canadian Cancer Trials Group
National Cancer Institute (NCI)
City of Hope Medical Center
Boundless Bio, Inc.
Novartis
Valo Therapeutics Oy
Numab Therapeutics AG
NextPoint Therapeutics, Inc.
BeiGene
Xencor, Inc.
BioEclipse Therapeutics
Corvus Pharmaceuticals, Inc.
Tempest Therapeutics
Eli Lilly and Company
Tocagen Inc.
CytoMed Therapeutics Pte Ltd
Merrimack Pharmaceuticals
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)